Publication details

Efficacy and Safety of Sarilumab for Noninfectious Uveitis of Posterior Segment: Outcomes From the Phase 2 SATURN Trial

Authors

HEISSIGEROVÁ Jarmila CALLANAN David DE SMET Marc SRIVASTAVA Sunil K. KARKANOVÁ Michala GARCIA-GARCIA Olga KADAYIFCILAR Sibel

Year of publication 2019
Type Article in Periodical
Magazine / Source Ophthalmology
Citation
Web http://dx.doi.org/10.1016/j.ophtha.2018.09.044
Doi http://dx.doi.org/10.1016/j.ophtha.2018.09.044
Keywords Sarilumab, rear uveitis, anti-interleukin-6 receptor antibody
Description To assess efficacy and safety of sarilumab, a human anti-interleukin-6 receptor antibody, for treatment of posterior segment noninfectious uveitis (NIU).Subcutaneous sarilumab may provide clinical benefits in the management of NIU of the posterior segment, especially in eyes with uveitic macular edema.

You are running an old browser version. We recommend updating your browser to its latest version.

More info